BTC Capital Management Inc. Makes New $442,000 Investment in Lantheus Holdings, Inc. (NASDAQ:LNTH)

BTC Capital Management Inc. bought a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 5,305 shares of the medical equipment provider’s stock, valued at approximately $442,000.

A number of other large investors have also added to or reduced their stakes in LNTH. Fairfield Bush & CO. bought a new position in Lantheus in the first quarter worth about $177,000. Raymond James & Associates purchased a new stake in shares of Lantheus during the first quarter worth about $856,000. Bank of New York Mellon Corp grew its stake in shares of Lantheus by 2.7% during the first quarter. Bank of New York Mellon Corp now owns 629,033 shares of the medical equipment provider’s stock worth $34,791,000 after acquiring an additional 16,422 shares during the last quarter. American Century Companies Inc. grew its stake in shares of Lantheus by 14.4% during the first quarter. American Century Companies Inc. now owns 19,235 shares of the medical equipment provider’s stock worth $1,064,000 after acquiring an additional 2,427 shares during the last quarter. Finally, HighTower Advisors LLC purchased a new stake in shares of Lantheus during the first quarter worth about $354,000. 99.06% of the stock is currently owned by institutional investors.

Lantheus Trading Down 1.1 %

Shares of NASDAQ:LNTH opened at $64.10 on Tuesday. Lantheus Holdings, Inc. has a 12-month low of $47.46 and a 12-month high of $100.85. The company has a market capitalization of $4.39 billion, a PE ratio of 156.34 and a beta of 0.68. The business has a 50 day moving average of $73.57 and a two-hundred day moving average of $81.84. The company has a current ratio of 4.88, a quick ratio of 4.55 and a debt-to-equity ratio of 1.01.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Thursday, August 3rd. The medical equipment provider reported $1.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.23 by $0.17. Lantheus had a return on equity of 67.18% and a net margin of 2.97%. The company had revenue of $321.70 million during the quarter, compared to the consensus estimate of $306.48 million. As a group, analysts forecast that Lantheus Holdings, Inc. will post 5.19 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Truist Financial restated a “buy” rating and set a $125.00 price target on shares of Lantheus in a research note on Friday. TheStreet upgraded Lantheus from a “c” rating to a “b-” rating in a research note on Wednesday, August 9th. Finally, StockNews.com began coverage on Lantheus in a research report on Thursday, August 17th. They issued a “buy” rating on the stock. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $121.83.

Insider Buying and Selling at Lantheus

In other news, CAO Andrea Sabens sold 1,752 shares of the company’s stock in a transaction that occurred on Wednesday, July 19th. The stock was sold at an average price of $90.87, for a total transaction of $159,204.24. Following the completion of the transaction, the chief accounting officer now directly owns 59,767 shares of the company’s stock, valued at approximately $5,431,027.29. The sale was disclosed in a filing with the SEC, which is available at this link. In other Lantheus news, President Paul Blanchfield sold 408 shares of the company’s stock in a transaction on Monday, August 21st. The stock was sold at an average price of $66.10, for a total value of $26,968.80. Following the completion of the sale, the president now directly owns 90,067 shares in the company, valued at approximately $5,953,428.70. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CAO Andrea Sabens sold 1,752 shares of the company’s stock in a transaction on Wednesday, July 19th. The shares were sold at an average price of $90.87, for a total value of $159,204.24. Following the completion of the sale, the chief accounting officer now owns 59,767 shares of the company’s stock, valued at $5,431,027.29. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 19,315 shares of company stock valued at $1,353,773. 1.50% of the stock is owned by company insiders.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable Tc-99m-labeled imaging agent.